Study of drug 3HP-2827 for tumors with FGFR2 changes
Part of Cancer clinical trials.
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have an advanced solid tumor (cannot be removed with surgery or has spread) that has a change in the FGFR2 gene.
- You must be in fairly good health (able to care for yourself and do light activities).
- You must not have active brain metastases (cancer that has spread to the brain and is causing symptoms).
- You must not have had another cancer in the last 3 years (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 3HP-327, for people with advanced solid tumors that have certain changes in the FGFR2 gene and have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new drug, KNT-0916, for people with advanced solid tumors that have a specific change in the FGFR2 gene. It may be an option if other treatments haven't worked or aren't available.
This study tests an experimental oral drug (CSCJC3456) that may target certain genetic changes (FGFR) in advanced cancers. It might be an option if your cancer has not improved with standard treatments.
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
This trial tests a new drug, HRS-7058, combined with other anti-cancer drugs for people with advanced solid tumors that cannot be surgically removed. The goal is to see if the combination can shrink tumors or slow their growth.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
Hear when a new Solid Tumors With FGFR2 Alterations, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.